4th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R & D Summit
With the great success of first three meetings on Bioavailability and Bioequivalence, BIOBIO-2010, BABE-2011 and BABE-2012; OMICS Group, the World Class Open Access Publisher and Scientific Events Organizer would like to have this privilege of inviting you to the 4th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R & D Summit (BABE-2013) held during May 20-22, 2013 DoubleTree by Hilton Beijing, China.
OMICS Group would like to invite you to be a speaker at BABE-2013. You are welcome to join us and give a speech on any of the topics based on call for abstracts. For call for abstracts:
The event BIOBIO-2010, BABE-2011 and BABE-2012 International conferences focused exclusively on various areas related to Bioavailability & Bioequivalence studies have attracted more than 150 eminent speakers from 20 countries which include esteemed scientists from prestigious Universities and eminent personalities from United States Food and Drug Administration (USFDA). The events were supported and sponsored by Agilent Technologies, USA; Cetero Research, USA; Pharmaceutics International Inc, USA; Absorption Systems, USA; AstraZeneca, USA; Baxter International Inc., USA; Merck Research Laboratories, USA; Nestle, Switzerland; GlaxoSmithKline, USA; Pfizer Inc., USA and many more..
The main theme of BABE-2013 is “Advanced Discussions of the Current Issues & Analyzing the Novel Approaches of Bioavailability & Bioequivalence".
BABE-2013 is a scientific platform to meet fellow key decision makers all-around the Academic Institutions, Healthcare Institutes, Pharmaceutical, Biotech, CROs supply chain, Logistics practitioners making the congress a perfect platform to share experience, foster collaborations through the research talks & presentations to put forward many thought provoking strategies in Bioequivalence and Bioavailability, making the congress a perfect platform to share proficiency.
|Ping Ren, CDER/FDA, USA
Lang Tiange, Chinese Academy of Sciences, China
Sudhakar Akul Yakkanti, USA
Shunlin Ren, Virginia Commonwealth University, USA
Peisheng Xu, University of South Carolina, USA
Su Chen, The Chainon Neurotrophin Biotechnology Inc. USA
Jun Zhang, Abbott Laboratories, USA
Shein-Chung Chow, Duke University School of Medicine, USA
Hideko Kaji, Thomas Jefferson University, USA
Ting-Chao Chou, Memorial Sloan-Kettering Cancer Center, USA
Camellia M Okpodu Norfolk State University, USA
|Xiaojian Jiang, CDER/FDA, USA
Sinerik N. Ayrapetyan, UNESCO, Armenia
Yasuo Iwasaki, Toho University Medical Center, Japan
Yibin Feng, The University of Hong Kong, Hong Kong
Dionysios Douroumis, Univeristy of Greenwich, UK
John Loudon, Wetherill Park Medical Centre, Australia
Magdy Mohammed, National Research Centre, Egypt
Neelesh Varde, University of Illinois, USA
Pradip K Mazumder, Krish Biotech, India
Rajeev Jain, Jiwaji University, India
Tapas Mandal, Saha Institute of Nuclear Physics, India
BABE-2013 is supported by Journal of Bioequivalence & Bioavailability, Journal of Bioanalysis & Biomedicine and Pharmaceutica Analytica Acta
The opinions expressed and information shared are those of the writer's and commentators; do not necessarily reflect that of Scientific Bangladesh.Scientific Bangladesh accepts no responsibility, legal or otherwise, for the accuracy or content of writers' and commentators' opinion and information.